Anaphylaxis after vaccination is among the rarest serious adverse events in medicine, occurring at a rate of roughly 1.3 cases per million doses administered across all routine vaccines. That figure comes from large population-based studies and passive surveillance data in the United States, and while certain vaccines and certain people carry modestly different risk profiles, the overall picture is consistent: for any given shot, the chance of a life-threatening allergic reaction rounds to something like one in a million. What makes the topic worth a closer look is that the real rate is probably a bit higher than official reports suggest, that the mRNA COVID-19 vaccines briefly appeared to change the calculus, and that specific personal risk factors can shift the odds meaningfully for a small number of people.
Where the One-in-a-Million Figure Comes From
The most widely cited estimate for post-vaccination anaphylaxis draws on a study that tracked over 25 million vaccine doses administered through a large U.S. health system. Researchers identified 33 confirmed anaphylaxis cases across that enormous denominator, producing a rate of about 1.31 per million doses.1PubMed Central. Risk of anaphylaxis after vaccination in children and adults A separate analysis of reports submitted to the U.S. Vaccine Adverse Event Reporting System between 1990 and 2016 arrived at essentially the same number: 1.3 cases per million doses.2Journal of Allergy and Clinical Immunology. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016 The consistency across two very different data sources gives the estimate credibility, though both have limitations worth understanding.
The population-based study used medical records and allergy specialist review to confirm every case, which is the gold standard for accuracy but means some milder anaphylaxis episodes treated and resolved in the field could have been missed. The surveillance system data, by contrast, relies on voluntary reports from healthcare providers and patients, which introduces its own biases. Still, the fact that both methods land in the same narrow range suggests the true rate for conventional vaccines is somewhere in that neighborhood.
Did COVID-19 Vaccines Change the Picture?
When the Pfizer-BioNTech and Moderna mRNA vaccines rolled out in late 2020, early case reports made it look like anaphylaxis was happening more often than expected. Clusters of reactions among healthcare workers in the first weeks of the campaign attracted intense media attention. Initial estimates placed the rate of anaphylaxis after mRNA COVID-19 vaccines at around 4.2 cases per million doses, with broader estimates ranging from roughly 2 to 11 per million depending on the data source and how strictly anaphylaxis was defined.3Vaccine. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration That is higher than the historical baseline for routine vaccines, but the gap narrowed as more data accumulated and researchers controlled for heightened surveillance and inconsistent case definitions. The true incidence of anaphylaxis to mRNA vaccines now appears comparable to that of other vaccines, with the early signal likely inflated by a combination of intense reporting scrutiny and broad definitions that swept in reactions that did not meet strict criteria.4PubMed Central. Fear, facts, and the future: An update on coronavirus disease 2019 vaccine-induced anaphylaxis and vaccine hesitancy among those living with allergy
An Australian study that examined cases where adrenaline (epinephrine) was administered after COVID-19 vaccination illustrates why early numbers ran high. Of 222 cases where adrenaline was given, only about 14% met the strictest criteria for confirmed anaphylaxis. A large share fell into lower diagnostic certainty categories or turned out not to be anaphylaxis at all.4PubMed Central. Fear, facts, and the future: An update on coronavirus disease 2019 vaccine-induced anaphylaxis and vaccine hesitancy among those living with allergy Anxiety-driven symptoms, vasovagal reactions, and garden-variety hives were frequently lumped in with genuine anaphylaxis during the early months, especially in mass vaccination sites where the clinical bar for using epinephrine was deliberately low.
What in a Vaccine Actually Causes Anaphylaxis
Vaccines contain more than just the active ingredient. Stabilizers, preservatives, and other inactive components called excipients are part of every formulation, and they are the usual suspects when anaphylaxis occurs. For the mRNA COVID-19 vaccines, two excipients drew particular scrutiny: polyethylene glycol (PEG) and polysorbate 80. PEG is used in the lipid nanoparticle shell that protects the fragile mRNA, and polysorbate 80 appears in other vaccine formulations as well as in many common medications and even cosmetics.
Allergy testing in patients who reacted to mRNA vaccines has found that a meaningful proportion test positive for sensitivity to PEG, polysorbate 80, or both. One study of patients evaluated after vaccine reactions found that about 13% were positive on skin testing for one or both excipients, a higher proportion than researchers anticipated.5PubMed Central. Polyethylene Glycol and Polysorbate 80 Skin Tests in the Context of an Allergic Risk Assessment for Hypersensitivity Reactions to Anti-SARS-CoV-2 mRNA Vaccines Work from Qatar found that among patients who experienced anaphylaxis after vaccination, half had positive allergy test results to these excipients.6Frontiers in Allergy. Challenges in diagnosing polyethylene glycol and polysorbate 80 allergies: implications for allergic reactions in COVID-19 mRNA vaccination program: experience from Qatar
The relationship between PEG and polysorbate 80 allergy is itself complicated. Some people’s immune systems recognize a short molecular fragment shared by both compounds, meaning that a person allergic to PEG may also react to polysorbate 80 and vice versa. But others react to polysorbate 80 through a completely independent mechanism that has nothing to do with PEG.7The Journal of Allergy and Clinical Immunology: In Practice. Endotyping of IgE-Mediated Polyethylene Glycol and/or Polysorbate 80 Allergy This matters because it means you cannot assume that someone who tolerated a polysorbate-containing vaccine will tolerate a PEG-containing one, or the reverse.
Beyond classical allergy pathways, researchers have explored a separate mechanism called complement activation-related pseudoallergy, in which the lipid nanoparticle shell triggers an arm of the immune system that does not involve the traditional allergic antibody. Animal models suggest this pathway could contribute to some of the immediate reactions seen after mRNA vaccination, particularly in people who do not test positive for PEG or polysorbate allergy through standard skin testing.8PubMed Central. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor
Who Faces a Higher Risk
Not everyone walks into a vaccination appointment with the same baseline odds. The strongest personal risk factor is a prior history of anaphylaxis to anything, not just vaccines. One analysis found that people with a prior history of allergies faced roughly twice the rate of post-vaccine anaphylaxis compared to the general population, and those with a prior episode of anaphylaxis faced about seven times the rate.3Vaccine. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration Keep in mind that seven times a one-in-a-million event is still extremely rare in absolute terms.
Food allergy also showed up as a risk factor in a Canadian study of the 2009 pandemic influenza vaccine. People with food allergies had nearly four times the odds of anaphylaxis compared to those without, and having an acute respiratory infection at the time of vaccination raised the odds even further.9Vaccine. Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada The respiratory infection finding is not well understood but may relate to a primed or hyperactive immune state at the time of the shot.
Sex is another factor. Women consistently report allergic adverse events after vaccination at higher rates than men. In data from Israel’s Pfizer-BioNTech rollout, the female-to-male ratio for allergic events after the first dose ranged from about 1.8 in the youngest age group to nearly 5 among adults in their sixties.10PubMed Central. Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine This female predominance is not unique to vaccines; women account for a disproportionate share of anaphylaxis cases from all triggers, likely reflecting differences in immune regulation and hormonal influences on mast cell biology.
People with mast cell disorders, a group of conditions in which the cells that release histamine are abnormally abundant or reactive, might seem like obvious candidates for higher risk. In practice, the data have been reassuring. An Italian study of patients with mast cell activation disorders found that only about 4.5% experienced an immediate hypersensitivity reaction after COVID-19 vaccination, and none of those reactions were severe anaphylaxis.11PubMed Central. Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy Expert consensus from European and American specialist networks recommends vaccination for these patients, noting that severe adverse reactions remain rare even in this high-risk group.12The Journal of Allergy and Clinical Immunology: In Practice. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
How Quickly Reactions Develop
Most vaccine-triggered anaphylaxis announces itself fast. In CDC data from the early Moderna COVID-19 vaccine rollout, the median time from injection to symptom onset was 7.5 minutes, with the full range spanning from 1 minute to 45 minutes.13PubMed Central. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine – United States, December 21, 2020-January 10, 2021 This rapid onset is why vaccination sites ask you to wait 15 minutes after your shot, or 30 minutes if you have a history of severe allergies. That observation window catches the vast majority of reactions while trained staff and epinephrine are at hand.
A less common but important pattern is the biphasic reaction, where symptoms resolve after initial treatment but then return hours later without re-exposure. Case reports describe patients discharged from emergency departments after successful treatment of anaphylaxis only to develop a second wave of symptoms requiring another round of epinephrine.14PubMed Central. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine Biphasic reactions are estimated to occur in a small fraction of anaphylaxis cases from any trigger, but they are the reason emergency physicians often recommend extended observation or at minimum prescribe a take-home epinephrine auto-injector after treating a first episode.
Why Reported Rates Probably Undercount the Real Number
The surveillance systems used to track vaccine adverse events have a known blind spot for anaphylaxis. VAERS, the primary U.S. passive surveillance system, captures only a fraction of cases that actually occur. A study comparing VAERS reports against confirmed cases identified through active medical record review found that VAERS captured between 13% and 76% of anaphylaxis cases depending on the vaccine in question. For seasonal influenza vaccine, for example, just 13% of confirmed anaphylaxis cases showed up in VAERS reports.15PubMed Central. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome
This underreporting does not mean the true rate of anaphylaxis is wildly higher than published estimates. The population-based studies that produce the 1.3-per-million figure use active case-finding in medical records, not passive reporting, so they partially correct for this gap. But it does mean that comparing raw VAERS counts between different vaccines, or between vaccines and other products, can be misleading. A vaccine with better reporting infrastructure will look more dangerous than one where reactions go unrecorded, even if both carry the same actual risk.
Standardized case definitions help, but they introduce their own challenges. The Brighton Collaboration maintains an internationally recognized case definition for anaphylaxis that assigns levels of diagnostic certainty, intended to make comparisons across countries and time periods more reliable.16PubMed. Anaphylaxis: Revision of the Brighton collaboration case definition The problem is that different studies apply these criteria with varying rigor. A study that accepts lower certainty levels will find more “anaphylaxis” than one that demands the highest tier. This is a large part of why estimates for COVID-19 vaccine anaphylaxis ranged from 2 to 11 per million in different analyses: the underlying biology was probably the same, but the diagnostic yardstick was not.
What Happens If You React to a First Dose
A question that many people with allergies ask is whether they can safely receive a second dose after reacting to the first. The answer for most people is yes, though the path involves allergist evaluation rather than simply getting the next shot at a pharmacy. A European study followed 55 patients who had reactions to their first COVID-19 vaccine dose. After allergy workup, 52 of them were revaccinated without adverse reactions. The researchers found no confirmed cases of true anaphylaxis on re-evaluation, suggesting that many first-dose reactions that looked like anaphylaxis in the moment turned out to be less severe allergic or anxiety-related events.17PubMed Central. Patients with suspected allergic reactions to COVID‐19 vaccines can be safely revaccinated after diagnostic work‐up
For people who did have confirmed anaphylaxis, graded dose challenges under medical supervision have been used successfully. In a graded challenge, the vaccine is given in small, incrementally increasing amounts while the patient is closely monitored. Case series have documented successful revaccination through this approach even in patients whose initial reactions were severe.18PubMed Central. CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes In some instances, switching to a vaccine made with different excipients is enough to avoid a repeat reaction entirely.
Updated guidance from the American Academy of Allergy, Asthma & Immunology actually recommends against routine skin testing with the vaccine or its excipients as a way to predict who will react. The reason is that skin testing has not proven reliable enough to change clinical decisions: a negative test does not guarantee safety, and a positive test does not necessarily mean the person will have a serious reaction.19Journal of Allergy and Clinical Immunology. Management of allergic reactions to mRNA COVID-19 vaccines: Updated guidance from the American Academy of Allergy, Asthma & Immunology Instead, the guidance favors a clinical history-based approach, where decisions about revaccination are made based on the severity and character of the first reaction rather than on test results.
Do Individual Vaccines Carry Noticeably Different Risks
When researchers have compared rates across specific vaccines, the differences are modest and often within each other’s margins of statistical uncertainty. In the large U.S. population study, the rate for inactivated trivalent influenza vaccine was about 1.35 per million doses, and for the inactivated monovalent influenza vaccine used during the 2009 pandemic it was roughly 1.83 per million, though the confidence intervals on that second number were wide because only two cases were identified.1PubMed Central. Risk of anaphylaxis after vaccination in children and adults Other routine childhood and adult vaccines fell within the same general range.
The one area where rates appeared higher, at least initially, was the mRNA COVID-19 vaccines. But as discussed earlier, much of the apparent elevation reflected surveillance intensity and loose case definitions rather than a genuine biological outlier. The gelatin used in some live vaccines (like MMR and varicella) and the egg protein residue in some influenza vaccines have historically been blamed for reactions, but confirmed anaphylaxis traceable to these components is quite rare. Modern formulations of flu vaccines contain trace amounts of egg protein far below the threshold needed to trigger a reaction in most egg-allergic individuals, and current guidelines no longer recommend against flu vaccination for people with egg allergy.
Preparedness at the Point of Vaccination
One reason vaccine-induced anaphylaxis almost never ends in death is that it happens in a medical or quasi-medical setting where treatment is immediately available. Epinephrine, the first-line treatment for anaphylaxis from any cause, acts within minutes to reverse airway swelling, raise blood pressure, and halt the allergic cascade. Vaccination sites, including pharmacies that administer shots, are expected to have written emergency protocols posted, trained staff who can recognize anaphylaxis, and epinephrine on hand.20Journal of Pharmacy Practice and Research. Managing vaccine‐associated anaphylaxis in the pharmacy
The 15- to 30-minute observation window after vaccination is calibrated to the onset data: since the vast majority of reactions start within that window, staying put gives staff a chance to intervene before symptoms escalate. For the rare individual whose symptoms begin after leaving the site, self-administered epinephrine via an auto-injector and a call to emergency services remain effective. Fatal anaphylaxis from vaccination, while not zero, is extraordinarily uncommon in the modern era precisely because the reaction happens where people are watching for it.
Allergy, Anaphylaxis, and Vaccine Hesitancy
Fear of allergic reactions is a measurable driver of vaccine avoidance, and it persists even among people whose allergy history does not place them at elevated risk. Surveys have found that hesitancy related to anaphylaxis concerns extends beyond those with documented allergies and into the general population, fueled in part by early media coverage of reactions during the COVID-19 vaccine rollout.4PubMed Central. Fear, facts, and the future: An update on coronavirus disease 2019 vaccine-induced anaphylaxis and vaccine hesitancy among those living with allergy The irony is that the same people most worried about vaccine reactions are often the ones most vulnerable to the infections vaccines prevent, because allergic and immunologic conditions can complicate infectious disease outcomes.
What allergists have found most useful in these conversations is not dismissing the concern but contextualizing the risk. A one-in-a-million event is roughly the odds of being struck by lightning in a given year. The risk from the disease a vaccine prevents is, in virtually every case, orders of magnitude higher. And unlike lightning, anaphylaxis from a vaccine is treatable on the spot, with a fatality rate that approaches zero when epinephrine is available. For the small number of people with confirmed excipient allergies or prior vaccine anaphylaxis, the conversation shifts from whether to vaccinate to how, with graded dosing, alternative formulations, and supervised settings as practical options rather than reasons to forgo vaccination entirely.